Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia

NACompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

August 5, 2022

Study Completion Date

March 1, 2023

Conditions
Community-acquired Pneumonia
Interventions
DEVICE

Antibiotic therapy according to the result of mPCR (device)

"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."

Trial Locations (1)

75018

Hôpital BICHAT, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03452826 - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia | Biotech Hunter | Biotech Hunter